Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial

This publication has 14 references indexed in Scilit:

• Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year Results
  JNCI Journal of the National Cancer Institute, 2000
• Phase III Randomized Study of Cisplatin Versus Paclitaxel Versus Cisplatin and Paclitaxel in Patients With Suboptimal Stage III or IV Ovarian Cancer: A Gynecologic Oncology Group Study
  Journal of Clinical Oncology, 2000
• Erratum: Estimates of the worldwide mortality from 25 cancers in 1990.Int. J. Cancer,83, 18-29 (1999).
  International Journal of Cancer, 1999
• Estimates of the worldwide incidence of 25 major cancers in 1990
  International Journal of Cancer, 1999
• Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials
  British Journal of Cancer, 1998
• ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer
  The Lancet, 1998
• Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
  New England Journal of Medicine, 1996
• Long-term follow-up of patients with advanced ovarian cancer treated in randomised clinical trials
  British Journal of Cancer, 1995
• Impact of doxorubicin on survival in advanced ovarian cancer.
  Journal of Clinical Oncology, 1995
• Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project.
  Journal of Clinical Oncology, 1991